Indaptus Therapeutics (NASDAQ:INDP) Issues Earnings Results

Indaptus Therapeutics (NASDAQ:INDP) released its quarterly earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.46) by $1.45, Zacks reports.

Indaptus Therapeutics Trading Up 0.7%

INDP stock traded up $0.02 during trading on Friday, hitting $3.17. The company had a trading volume of 80,802 shares, compared to its average volume of 588,617. The business has a 50-day moving average of $2.92 and a 200-day moving average of $2.31. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $5.96. The stock has a market cap of $422.77 million, a PE ratio of -0.50 and a beta of 0.96.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways. The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease.